Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Payables (2016 - 2026)

Ocular Therapeutix has reported Payables over the past 14 years, most recently at $8.0 million for Q1 2026.

  • For Q1 2026, Payables rose 73.5% year-over-year to $8.0 million; the TTM value through Mar 2026 reached $8.0 million, up 73.5%, while the annual FY2025 figure was $4.2 million, 0.53% down from the prior year.
  • Payables for Q1 2026 was $8.0 million at Ocular Therapeutix, up from $4.2 million in the prior quarter.
  • Over five years, Payables peaked at $8.0 million in Q1 2026 and troughed at $3.4 million in Q1 2022.
  • A 5-year average of $5.0 million and a median of $4.6 million in 2025 define the central range for Payables.
  • Biggest five-year swings in Payables: plummeted 72.51% in 2022 and later surged 73.5% in 2026.
  • Year by year, Payables stood at $5.1 million in 2022, then dropped by 14.33% to $4.4 million in 2023, then dropped by 4.85% to $4.2 million in 2024, then fell by 0.53% to $4.2 million in 2025, then skyrocketed by 93.21% to $8.0 million in 2026.
  • Business Quant data shows Payables for OCUL at $8.0 million in Q1 2026, $4.2 million in Q4 2025, and $6.3 million in Q3 2025.